Answers are grounded in this paper and cite their sources.
Case report reveals ventricular bigeminy following subcutaneous apomorphine in Parkinson's disease, highlighting potential cardiac arrhythmogenic risks.
Apomorphine is a well established treatment for the management of sudden, unexpected and refractory levodopa-induced "off" states in fluctuating Parkinson's disease either as bolus injections or as continuous infusions. Incidents of atrial fibrillation associated with the administration of the drug have been reported in the past but no incidents of ventricular arrhythmias. We report a case of ventricular bigeminy recorded in a female patient after the administration of apomorphine.
No takes yet. Share an insight, caveat, or question.
Kaminioti et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: